Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Vertex Pharmaceuticals logo
$404.88 +13.25 (+3.38%)
As of 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Advanced

Key Stats

Today's Range
$392.50
$407.50
50-Day Range
$366.54
$476.95
52-Week Range
$362.50
$519.88
Volume
1.06 million shs
Average Volume
1.65 million shs
Market Capitalization
$103.81 billion
P/E Ratio
28.95
Dividend Yield
N/A
Price Target
$493.81
Consensus Rating
Moderate Buy

Company Overview

Vertex Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

VRTX MarketRank™: 

Vertex Pharmaceuticals scored higher than 95% of companies evaluated by MarketBeat, and ranked 42nd out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 15 buy ratings, 11 hold ratings, and no sell ratings.

  • Upside Potential

    Vertex Pharmaceuticals has a consensus price target of $493.81, representing about 21.8% upside from its current price of $405.37.

  • Amount of Analyst Coverage

    Vertex Pharmaceuticals has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vertex Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vertex Pharmaceuticals is 28.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 282.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vertex Pharmaceuticals is 28.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.01.

  • Price to Book Value per Share Ratio

    Vertex Pharmaceuticals has a P/B Ratio of 6.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vertex Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.58% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently increased by 11.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vertex Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vertex Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.58% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently increased by 11.26%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Vertex Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 38 news articles for Vertex Pharmaceuticals this week, compared to 39 articles on an average week.
  • Search Interest

    Only 69 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    36 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 177% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vertex Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,948,400.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vertex Pharmaceuticals' insider trading history.
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Stock News Headlines

Leerink Partnrs Issues Negative Forecast for VRTX Earnings
5 Top Stocks to Buy in October
RIP USA
"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fund firm manager who predicted 2008 and 2020 just issued. He says if you're over 50, there's one urgent move you need to make to survive... or risk getting left behind.tc pixel
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to "Strong-Buy" at Leerink Partnrs
Leerink Partnrs Analysts Cut Earnings Estimates for VRTX
See More Headlines

VRTX Stock Analysis - Frequently Asked Questions

Vertex Pharmaceuticals' stock was trading at $402.70 at the beginning of the year. Since then, VRTX shares have increased by 0.7% and is now trading at $405.3650.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Monday, August, 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. The business's revenue for the quarter was up 11.3% compared to the same quarter last year.
Read the conference call transcript
.

Vertex Pharmaceuticals subsidiaries include V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Vertex Pharmaceuticals' top institutional investors include Praxis Investment Management Inc.. Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Sangeeta N Bhatia and Yuchun Lee.
View institutional ownership trends
.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
8/04/2025
Today
10/01/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CIK
875320
Employees
6,100
Year Founded
1989

Price Target and Rating

High Price Target
$575.00
Low Price Target
$405.00
Potential Upside/Downside
+26.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
28 Analysts

Profitability

EPS (Trailing Twelve Months)
$13.99
Trailing P/E Ratio
27.99
Forward P/E Ratio
25.06
P/E Growth
N/A
Net Income
-$535.60 million
Net Margins
31.86%
Pretax Margin
38.31%
Return on Equity
23.91%
Return on Assets
17.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.52
Quick Ratio
2.16

Sales & Book Value

Annual Sales
$11.02 billion
Price / Sales
9.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$63.72 per share
Price / Book
6.15

Miscellaneous

Outstanding Shares
256,390,000
Free Float
255,878,000
Market Cap
$100.41 billion
Optionable
Optionable
Beta
0.44

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:VRTX) was last updated on 10/1/2025 by MarketBeat.com Staff
From Our Partners